NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
FORT WORTH (October 23, 2023) — NanOlogy LLC, a clinical-stage oncology company, announced today that an abstract has been accepted for poster presentation at the 38th Society for Immunotherapy of Cancer (SITC) annual meeting being held November 1-5 at the San Diego Convention Center.
The abstract (#1084) entitled: “Local administration of large surface area microparticle docetaxel is associated with anti-tumor immunomodulation across multiple tumor types” will be presented in Exhibit Hall B of the convention center during poster sessions throughout the day on Saturday, November 4th.
A press release summarizing presentation data will be issued following the conference.
NanOlogy, LLC (www.nanology.us) is a private clinical-stage oncology company formed in 2015 to improve the treatment of solid tumors with investigational drugs optimized for intratumoral delivery by a proprietary particle engineering technology platform. NanOlogy clinical programs have advanced investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The investigational drugs are covered by composition of matter patents issued in the US (9,814,685, 10,507,195, 10,993,927, and 11,123,322), and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, Australia, and India valid through June 2036. The composition patents form the foundation of an extensive intellectual property portfolio of over 130 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology.
Opus Biotech Communications